Abstract
We have previously demonstrated that side population (SP) cells derived from endometrial cancer cells have cancer stem-like cell features. However, the role of stem cell-enriched subpopulations, SP cells in normal endometrium for carcinogenesis is still poorly understood. In the present study, to modeled early carcinogenesis in normal endometrium, we established two cell lines by introducing the oncogenic KRAS gene into SP (RSP) cells and non-SP (RNSP) cells from a rat non-tumorigenic endometrial cell line. Tumorigenicity was enhanced in SP cells harboring mutant KRAS (RSP-K12V cells) compared with that in NSP harboring mutant KRAS gene (RNSP-K12V cells). The primary cultured tumor cells derived from RSP-K12V cells exhibited long-term proliferating capacity in culture and had the capacity to form serial tumors in vivo. In contrast, the primary cultured tumor cells derived from RNSP-K12V cells failed to grow and became senescent. The proportion of SP cells was higher in RSP-K12V cells than in RSP cells and was highest in the RSP-K12V tumor cells and it was correlated with tumorigenicity. The levels of c-Myc and Oct4, and the transcriptional activity of the estrogen receptor were enhanced in RSP-K12V cells and their tumor cells compared with those in RNSP-K12V cells and their tumor cells, respectively. Tumor cells derived RSP-K12V acquired the potential for estrogen-independent proliferation. This is the first report which demonstrates that the occurrence of KRAS gene mutations in SP cells rather than NSP cells derived from nontumorigenic endometrial cells, contributes to the development of malignant endometrial tumors.
Highlights
Endometrial cancer (EC) is the most common gynecological malignancy in the industrialized world
Tumorigenicity was enhanced in side population (SP) cells harboring mutant KRAS compared with that in NSP harboring mutant KRAS gene
We investigated the role of SP cells in nontumorigenic endometrial cells for development of endometrial cancer
Summary
Endometrial cancer (EC) is the most common gynecological malignancy in the industrialized world. It is classified into one of two clinicopathological types. The first, type I, is estrogen-related ECs, develops in pre-and postmenopausal women, has endometrioid histology, and is frequently preceded by endometrial hyperplasia. The second, type II, is non-estrogen-related ECs, occurs in postmenopausal women, encompasses histologies other than endometrioid type (mainly papillary serous or clear cell carcinomas), and is not associated with hyperplasia. The most frequent genetic alteration in type I endometrioid carcinoma is PTEN inactivation, followed by microsatellite instability, and mutations of the KRAS and β-catenin. In type II cancer, TP53 mutation is the most frequent genetic alteration, followed by amplification of ERBB2 [1]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
